Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
Innovative Capsugel Enprotect capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the US
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Subscribe To Our Newsletter & Stay Updated
